Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria C Cid

Showing results (101-110 of 143) with videos related to

Pageof 15
Sort By:
Rheumatology (Oxford, England)|September 19, 2025
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score studyAdriana Soto-Peleteiro, José Hernández-Rodríguez, Fátima Raad, et al.
Arthritis and Rheumatism|December 16, 2003
Domains of health-related quality of life important to patients with giant cell arteritisDavid B Hellmann, Misty L Uhlfelder, John H Stone, et al.
Autoimmunity Reviews|August 25, 2015
Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference centerJosé Hernández-Rodríguez, Estíbaliz Ruíz-Ortiz, Adrià Tomé, et al.
Frontiers in Immunology|March 10, 2023
Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritisMaxime Samson, Coraline Genet, Marc Corbera-Bellalta, et al.
Journal of Autoimmunity|December 1, 2023
Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritisHélène Greigert, André Ramon, Coraline Genet, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitisJonathan Steinfeld, Eric S Bradford, Judith Brown, et al.
The New England Journal of Medicine|May 18, 2017
Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisMichael E Wechsler, Praveen Akuthota, David Jayne, et al.
Annals of the Rheumatic Diseases|April 30, 2013
Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritisMarc Corbera-Bellalta, Ana García-Martínez, Ester Lozano, et al.
RMD Open|January 5, 2018
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patientsSergio Prieto-González, Nekane Terrades-García, Marc Corbera-Bellalta, et al.
Arthritis and Rheumatism|October 13, 2011
Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemiaMattia Baldini, Norma Maugeri, Giuseppe A Ramirez, et al.
Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
Rheumatology (Oxford, England)|September 19, 2025
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score studyAdriana Soto-Peleteiro, José Hernández-Rodríguez, Fátima Raad, et al.
Arthritis and Rheumatism|December 16, 2003
Domains of health-related quality of life important to patients with giant cell arteritisDavid B Hellmann, Misty L Uhlfelder, John H Stone, et al.
Autoimmunity Reviews|August 25, 2015
Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference centerJosé Hernández-Rodríguez, Estíbaliz Ruíz-Ortiz, Adrià Tomé, et al.
Frontiers in Immunology|March 10, 2023
Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritisMaxime Samson, Coraline Genet, Marc Corbera-Bellalta, et al.
Journal of Autoimmunity|December 1, 2023
Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritisHélène Greigert, André Ramon, Coraline Genet, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitisJonathan Steinfeld, Eric S Bradford, Judith Brown, et al.
The New England Journal of Medicine|May 18, 2017
Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisMichael E Wechsler, Praveen Akuthota, David Jayne, et al.
Annals of the Rheumatic Diseases|April 30, 2013
Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritisMarc Corbera-Bellalta, Ana García-Martínez, Ester Lozano, et al.
RMD Open|January 5, 2018
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patientsSergio Prieto-González, Nekane Terrades-García, Marc Corbera-Bellalta, et al.
Arthritis and Rheumatism|October 13, 2011
Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemiaMattia Baldini, Norma Maugeri, Giuseppe A Ramirez, et al.
Pageof 15